Molecular pharmacology

Testing how drugs that selectively block a part of the brain’s NMDA receptor affect its function using drug interaction models

Updated

Abstract

TCN-201 has a binding affinity of 42 nM and negatively modulates glycine binding compared to MPX-004 and MPX-007.

  • GluN2A-selective negative allosteric modulators exhibit varying effects on glycine binding affinity and agonist efficacy.
  • MPX-004 demonstrates a stronger binding affinity (K = 9.3 nM) and increases agonist efficacy (β = 1.19) compared to TCN-201 and MPX-007.
  • TCN-201 and MPX-007 show weaker binding affinities (K = 42 nM and K = 1.1 nM, respectively) and reduce agonist efficacy (β = 0.76 and β = 0.82, respectively).
  • The pharmacological model used allows for a deeper understanding of the modulation of NMDA receptors and can aid in designing new therapeutic modulators.
  • The differences in modulation between these compounds may influence their potential utility as pharmacological tools.

Simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free